Curacytes scientists discorver new anti-tumor agents
Since the discovery of the gene in 1999, matriptase has increasingly gained attention as a potential biological target for inhibiting tumor spread. Today, matriptase is recognized as an innovative anti-cancer target. In in vitro assays, the Curacyte inhibitor series exhibit excellent affinity and selectivity towards the target and a pharmacokinetic profile that supports their use as pharmaceutically active substances.
Dr. Helmut Giersiefen, Chief Executive Officer of Curacyte AG, commented on the recent scientific success:
"The discovery of the matriptase inhibitors corroborates the validity and value of our protease technology. Based on our proprietary inhibitor libraries and our competence with respect to the chemistry of these substances, we have identified a series of novel potential anti-tumor agents, enabling us to move another important project into preclinical development. We will continue to derive therapeutically valuable applications from our protease technology that we can leverage with pharmaceutical partners."
Curacyte pursues the development of its protease technology in close collaboration with the Center of Vascular Biology and Medicine of the University of Jena (Germany) under the leadership of Dr. Jörg Stürzebecher, a well-known pioneer in the area of synthetic inhibitors of serine proteases.
"We are very proud of our collaboration with Curacyte," commented Dr. Stürzebecher. "The successful development of these matriptase inhibitors was possible by combining our knowledge of the structure-function relationship of protease inhibitors that we gained over decades with the competence in drug discovery and pharmaceutical development provided by Curacyte. Our collaboration on protease inhibitors, including matriptase has been ongoing for over two years and establishes a benchmark for the fruitful synergies that can be created by bringing together academic and commercial competencies."
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.